Across TCGA pan-cancer cohorts, RPS4X mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RPS4X data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RPS4X mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RPS4X expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

HNSC, CCRCC, and PDAC are the cancer types where RPS4X mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	III,IV	0.956	0.644	<.001	28	view →
CCRCC	OS	Tertile	All	0.642	1.000	.010	21	view →
PDAC	DFS	Median	IV	0.214	0.785	.006	15	view →
LUAD	DFS	Quartile	All	1.000	0.823	.005	10	view →
OV	DFS	Median	All	0.867	1.000	.030	4	view →
UCEC	DFS	Median	II,III,IV	0.534	0.867	.040	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

Exploration

Same gene, other analysis: RPS4X tumor-vs-normal RNA expression · all RPS4X data types